Emerging therapies in bone metastasis

Current Opinion in Pharmacology

Volumn 22, Issue , 2015, Pages 79-86

  Clément Demange, Lise ^a,b   Clézardin, Philippe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ATRASENTAN; BHQ 880; BISPHOSPHONIC ACID DERIVATIVE; BOSUTINIB; CABOZANTINIB; CATHEPSIN K; CATHEPSIN K INHIBITOR; DASATINIB; DOCETAXEL; ENDOTHELIN 1; EVEROLIMUS; EXEMESTANE; NERVE GROWTH FACTOR; ODANACATIB; PLACEBO; PREDNISONE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHBITOR; RADIOPHARMACEUTICAL AGENT; RADIUM 223; SARACATINIB; SCATTER FACTOR; SOTATERCEPT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; WNT INHIBITOR; ZIBOTENTAN; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DENSITY; BONE MARROW; BONE MATRIX; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CELL COMPARTMENTALIZATION; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; METASTASIS; MONOTHERAPY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; ANIMAL; BONE NEOPLASMS; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SECONDARY; TUMOR MICROENVIRONMENT;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOBLASTS; OSTEOCLASTS; TUMOR MICROENVIRONMENT;

EID: 84928716996     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.04.004     Document Type: Review

References (27)

1. L.C. Hofbauer, T.D. Rachner, R.E. Coleman, and F. Jakob Endocrine aspects of bone metastases Lancet Diabetes Endocrinol 2 2014 500512
2. R. Coleman, M. Gnant, G. Morgan, and P. Clézardin Effects of bone-targeted agents on cancer progression and mortality J Natl Cancer Inst 104 2012 1059 1067
3. K.N. Weilbaecher, T.A. Guise, and L.K. McCauley Cancer to bone: a fatal attraction Nat Rev Cancer 11 2011 411 424
4. P. Clézardin Therapeutic targets for bone metastases in breast cancer Breast Cancer Res 13 2011 207
5. H.G. Bone, D.W. Dempster, J.A. Eisman, S.L. Greenspan, M.R. McClung, T. Nakamura, S. Papapoulos, W.J. Shih, A. Rybak-Feiglin, and A.C. Santora et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial Osteoporos Int 26 2015 699 712
6. T. Duong le, G.A. Wesolowski, P. Leung, R. Oballa, and M. Pickarski Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis Mol Cancer Ther 13 2014 2898 2909
7. J.C. Araujo, G.C. Trudel, F. Saad, A.J. Armstrong, E.Y. Yu, J. Bellmunt, G. Wilding, J. McCaffrey, S.V. Serrano, and V.B. Matveev et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial Lancet Oncol 14 2013 1307 1316
8. M. Campone, I. Bondarenko, S. Brincat, Y. Hotko, P.N. Munster, E. Chmielowska, P. Fumoleau, R. Ward, N. Bardy-Bouxin, and E. Leip et al. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy Ann Oncol 23 2012 610 617
9. R. Dienstmann, J. Rodon, V. Serra, and J. Tabernero Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors Mol Cancer Ther 13 2014 1021 1031
10. A. Suvannasankha, and J.M. Chirgwin Role of bone-anabolic agents in the treatment of breast cancer bone metastasis Breast Cancer Res 16 2014 484
11. O. Hussein, K. Tiedemann, M. Murshed, and S.V. Komarova Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases Cancer Lett 314 2012 176 184
12. M. Gnant, J. Baselga, H.S. Rugo, S. Noguchi, H.A. Burris, M. Piccart, G.N. Hortobagyi, J. Eakle, H. Mukai, and H. Iwata et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2 J Natl Cancer Inst 105 2013 654 663
13. R.J. Broom, V. Hinder, K. Sharples, J. Proctor, S. Duffey, S. Pollard, P.C. Fong, G. Forgeson, D.L. Harris, and M.B. Jameson et al. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial Clin Genitourin Cancer 13 2015 50 58
14. L. Rosanò, F. Spinella, and A. Bagnato Endothelin 1 in cancer: biological implications and therapeutic opportunities Nat Rev Cancer 13 2013 637 651
15. M.D. Michaelson, D.S. Kaufman, P. Kantoff, W.K. Oh, and M.R. Smith Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer Cancer 107 2006 530 535
16. S. Lotinun, R.S. Pearsall, W.C. Horne, and R. Baron Activin receptor signaling: a potential therapeutic target for osteoporosis Curr Mol Pharmacol 5 2012 195 204
17. E. Terpos, E. Kastritis, D. Christoulas, M. Gkotzamanidou, E. Eleutherakis-Papaiakovou, N. Kanellias, A. Papatheodorou, and M.A. Dimopoulos Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy Ann Oncol 23 2012 2681 2686
18. K.M. Abdulkadyrov, G.N. Salogub, N.K. Khuazheva, M.L. Sherman, A. Laadem, R. Barger, R. Knight, S. Srinivasan, and E. Terpos Sotatercept in patients with osteolytic lesions of multiple myeloma Br J Haematol 165 2014 814 823
19. T. Chu, J. Teng, L. Jiang, H. Zhong, and B. Han Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation Biochem Biophys Res Commun 443 2014 962 968
20. M.R. McClung, A. Grauer, S. Boonen, M.A. Bolognese, J.P. Brown, A. Diez-Perez, B.L. Langdahl, J.Y. Reginster, J.R. Zanchetta, and S.M. Wasserman et al. Romosozumab in postmenopausal women with low bone mineral density N Engl J Med 370 2014 412 420
21. R.J. Lee, and M.R. Smith Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer Cancer J 19 2013 90 98
22. Elixis announces results from the COMET-1 phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer. Conference call on Tuesday, September 2, 2014 (http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=1962549).
23. P. Mantyh Bone cancer pain: causes, consequences, and therapeutic opportunities Pain 154 Suppl 1 2013 S54 S62
24. B.A. Gartrell, and F. Saad Managing bone metastases and reducing skeletal related events in prostate cancer Nat Rev Clin Oncol 11 2014 335 345
25. O. Sartor, R. Coleman, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O'Sullivan, S.D. Fosså, A. Chodacki, P. Wiechno, and J. Logue et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial Lancet Oncol 15 2014 738 746
26. M.I. Suominen, J.P. Rissanen, R. Käkönen, K.M. Fagerlund, E. Alhoniemi, D. Mumberg, K. Ziegelbauer, J.M. Halleen, S.M. Käkönen, and A. Scholz Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis J Natl Cancer Inst 105 2013 908 916
27. R. Coleman, A.K. Aksnes, B. Naume, C. Garcia, G. Jerusalem, M. Piccart, N. Vobecky, M. Thuresson, and P. Flamen A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease Breast Cancer Res Treat 145 2014 411 418